# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Seretide 500 Diskus 50 microgram/500 microgram/dose inhalation powder, pre-dispensed

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 47 micrograms of salmeterol (as salmeterol xinafoate) and 460 micrograms of fluticasone propionate. This corresponds to a pre-dispensed dose of 50 micrograms of salmeterol (as salmeterol xinafoate) and 500 micrograms fluticasone propionate.

#### Excipient(s) with known effect:

Each delivered dose contains up to 12.5 mg of lactose (as lactose monohydrate).

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Inhalation powder, pre-dispensed.

Product imported from Lithuania.

Moulded plastic device containing a foil strip with 60 regularly placed blisters.

#### **4 CLINICAL PARTICULARS**

As per PA1077/046/003

## **5 PHARMACOLOGICAL PROPERTIES**

As per PA1077/046/003

#### **6 PHARMACEUTICAL PARTICULARS**

#### 6.1 List of excipients

Excipient: Lactose monohydrate (which contains milk proteins).

### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf life expiry date for this product shall be the date shown on the packaging of the product on the market in the country of origin.

## 6.4 Special precautions for storage

Do not store above 30. Store in the original package in order to protect from moisture.

#### 6.5 Nature and contents of container

The inhalation powder is contained in blisters held on a formed PVC coated base, with a peelable foil laminate lid. The strip is contained in a moulded plastic device. The plastic device is available in a cardboard container, which holds 1 x 60 dose Diskus.

#### 6.6 Special precautions for disposal

02 June 2023 CRN00DG35 Page 1 of 2

# **Health Products Regulatory Authority**

The Diskus releases a powder which is inhaled into the lungs. A dose indicator on the Diskus indicates the number of doses left. For detailed instructions for use see the Patient Information Leaflet.

#### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Merit Pharmaceuticals Limited Unit C4/C3 Metropoint Business Park Kettles Lane Swords Co Dublin K67 RH92 Ireland

#### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA23080/028/002

# 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 2<sup>nd</sup> June 2023

10 DATE OF REVISION OF THE TEXT

02 June 2023 CRN00DG35 Page 2 of 2